HIF1A and postmenopausal osteoporosis: Thus, blocking HIF1α pharmacologically could represent an ideal treatment for postmenopausal osteoporosis, as it could target pathologically-activated osteoclasts without altering physiological osteoclastogenesis required for bone turnover.